Literature DB >> 34146198

Serum microRNA-33 levels in pre-diabetic and diabetic patients.

Beydolah Shahouzehi1, Mostafa Eghbalian2, Hossein Fallah3, Soheil Aminizadeh4, Yaser Masoumi-Ardakani5.   

Abstract

Diabetes mellitus (DM) is a metabolic disease characterized by hyperglycemia and abnormal insulin secretion. MicroRNAs are small, non-coding RNAs that are able to affect cell biological functions and act as biomarkers for some diseases such as DM. In current study, we measured serum miR-33 in three groups (n = 15) as follows; non-diabetic control, pre-diabetic, and DM patients. Real-time PCR method was used to quantify miR-33 expression. miR-33 expression was significantly increased in pre-diabetic subjects compared to other two groups (p < 0.001). FBS (p < 0.001), insulin (p < 0.001), HOMA-IR (p < 0.001), and TG (p = 0.026) were higher in diabetic subjects than the other two groups. In people that had high physical activity, the number of diabetic subjects were zero and most of them were in pre-diabetic group (p = 0.019). Serum miR-33 level significantly and positively correlated with pre-diabetic state (B = 2.67, p = 0.000), Sex (B = 1.03, p = 0.025), and FBS (B = 0.04, p = 0.036) and also miR-33 was significantly and negatively correlated with HOMA-IR (B = - 1.58, p = 0.04). These findings support the possible role of miR-33 to monitor pre-diabetes onset and progression. It needs to be evaluated in future studies with high number of participants to clarify its mechanism and diagnostic viability.

Entities:  

Keywords:  Diabetes mellitus; Insulin; Real-time PCR; miR-33

Mesh:

Substances:

Year:  2021        PMID: 34146198     DOI: 10.1007/s11033-021-06425-7

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  16 in total

Review 1.  Circulating microRNAs as novel biomarkers for diabetes mellitus.

Authors:  Claudiane Guay; Romano Regazzi
Journal:  Nat Rev Endocrinol       Date:  2013-04-30       Impact factor: 43.330

2.  Therapeutic Inhibition of miR-33 Promotes Fatty Acid Oxidation but Does Not Ameliorate Metabolic Dysfunction in Diet-Induced Obesity.

Authors:  Denuja Karunakaran; Laura Richards; Michele Geoffrion; Danyk Barrette; Ryan J Gotfrit; Mary-Ellen Harper; Katey J Rayner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-10-01       Impact factor: 8.311

3.  MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis.

Authors:  S Hani Najafi-Shoushtari; Fjoralba Kristo; Yingxia Li; Toshi Shioda; David E Cohen; Robert E Gerszten; Anders M Näär
Journal:  Science       Date:  2010-05-13       Impact factor: 47.728

4.  miRNAs and diabetes mellitus.

Authors:  Dwi Setyowati Karolina; Arunmozhiarasi Armugam; Sugunavathi Sepramaniam; Kandiah Jeyaseelan
Journal:  Expert Rev Endocrinol Metab       Date:  2012-05

5.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases.

Authors:  Xi Chen; Yi Ba; Lijia Ma; Xing Cai; Yuan Yin; Kehui Wang; Jigang Guo; Yujing Zhang; Jiangning Chen; Xing Guo; Qibin Li; Xiaoying Li; Wenjing Wang; Yan Zhang; Jin Wang; Xueyuan Jiang; Yang Xiang; Chen Xu; Pingping Zheng; Juanbin Zhang; Ruiqiang Li; Hongjie Zhang; Xiaobin Shang; Ting Gong; Guang Ning; Jun Wang; Ke Zen; Junfeng Zhang; Chen-Yu Zhang
Journal:  Cell Res       Date:  2008-10       Impact factor: 25.617

6.  miR33 inhibition overcomes deleterious effects of diabetes mellitus on atherosclerosis plaque regression in mice.

Authors:  Emilie Distel; Tessa J Barrett; Kellie Chung; Natasha M Girgis; Saj Parathath; Christine C Essau; Andrew J Murphy; Kathryn J Moore; Edward A Fisher
Journal:  Circ Res       Date:  2014-09-08       Impact factor: 17.367

7.  Identification of stress-related microRNA biomarkers in type 2 diabetes mellitus: A systematic review and meta-analysis.

Authors:  Ying-Zhi Liang; Jia-Jiang-Hui Li; Huan-Bo Xiao; Yan He; Ling Zhang; Yu-Xiang Yan
Journal:  J Diabetes       Date:  2018-02-13       Impact factor: 4.006

Review 8.  Role of microRNAs in diabetes and its cardiovascular complications.

Authors:  Saran Shantikumar; Andrea Caporali; Costanza Emanueli
Journal:  Cardiovasc Res       Date:  2011-11-07       Impact factor: 10.787

9.  Clinical Significance of Determining Plasma MicroRNA33b in Type 2 Diabetic Patients with Dyslipidemia.

Authors:  Yuki Kimura; Naoki Tamasawa; Koki Matsumura; Hiroshi Murakami; Maki Yamashita; Kota Matsuki; Jutaro Tanabe; Hiroshi Murakami; Jun Matsui; Makoto Daimon
Journal:  J Atheroscler Thromb       Date:  2016-06-15       Impact factor: 4.928

Review 10.  Molecular biomarkers in diabetes mellitus (DM).

Authors:  Seyed Mohsen Aghaei Zarch; Masoud Dehghan Tezerjani; Mehrdad Talebi; Mohammad Yahya Vahidi Mehrjardi
Journal:  Med J Islam Repub Iran       Date:  2020-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.